biomarker

Oncotelic and Sapu Nano Announce DeciparticleTM Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine

AGOURA HILLS, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano today…

2 weeks ago

Alamar Biosciences Launches NULISAqpcr BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer’s Disease Research

New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next generation of assay development.  FREMONT, Calif., Oct. 9,…

2 months ago

FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025: ALZHEIMER’S ASSOCIATION RELEASES ITS FIRST CLINICAL PRACTICE GUIDELINE FOR BLOOD-BASED BIOMARKER TESTS

Key Takeaways At AAIC 2025, the Alzheimer's Association released the first in a series of clinical practice guidelines for the…

5 months ago

Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort

NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 to Power Biomarker Discovery in 23,000 Longitudinal Samples FREMONT, Calif., July…

5 months ago

Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer’s Association International Conference (AAIC)

Groundbreaking Insights into Neurodegenerative Disease Biomarkers to be Unveiled through 30+ Posters and Presentations at International Meeting FREMONT, Calif., July…

5 months ago